Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development of $101.06M in Q2 FY2026
Q2 FY2026 research & development was $101.06M.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 109.11M USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.11M | — |
Research & Development vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 research & development of $109.11M is the 3rd highest of the 10 companies compared; the peer median is $70.7M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $509.32M | +227.9% | +85.3% | — | |
| LTM Jun 2026 | $148.75M | +4.1% | +17.8% | 2088.9% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $109.11M | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $101.27M | +35.7% | +54.7% | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $83.27M | +36.9% | +34.3% | 807.2% |
| LTM Mar 2026 | $70.7M | -6.3% | +29.5% | — | |
| LTM Mar 2026 | $66.77M | -12.8% | -2.0% | 185483.3% | |
| LTM Mar 2026 | $48.2M | -55.0% | -0.4% | — | |
| LTM Mar 2026 | $24.01M | +104.7% | +13.1% | 65.2% | |
| LTM Mar 2026 | $5.77M | -21.5% | -38.7% | — | |
| Peer median (excluding KLRA) | $70.7M | +4.1% | +17.8% | 1448.0% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 109.11M |
| Selling, General & Admin | 49.23M |
| Operating Expenses | 158.34M |
| Depreciation & Amortization | 310K |
| EBITDA | (158.03M) |
| EBITDA Margin | — |
| Operating Income | (158.34M) |
| Operating Margin | — |
| Interest Income | 11.05M |
| Interest Expense | 0 |
| Other Income / Expenses | 9.39M |
| Income Before Tax | (148.96M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (148.96M) |
| Net Margin | — |
| EPS (Basic) | (1.26) |
| EPS (Diluted) | (1.26) |
| Weighted Avg Shares | 117.95M |
| Weighted Avg Shares (Diluted) | 117.95M |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.